keyword
MENU ▼
Read by QxMD icon Read
search

Lung cancer AND anti-vegf

keyword
https://www.readbyqxmd.com/read/28156441/strategy-of-using-herbal-extract-preparations-for-stage-iv-cancer-in-palliative-care-an-enhanced-and-maintenance-therapy
#1
Zhang Lingyan, Zhou Xiaoxia, Yin Weihua, Zhang Xiulian, Liu Hong, Duan Xiaopeng, Yu Cui, Luo Xiaolu, Zhong Qingfeng, Zhao Fen, Li Xianyong
: 89 Background: Palliative care is focused and seems as rationally anti-cancer way that have low systemic toxicity and acceptable effectiveness for stage IV cancer, especially herbal extracted medicines, which can regulate tumor microenviroment and body immune system. Our previous lab studies have indicated that TGF-beta, EGF, VEGF, IL-10 cytokines expression and mico-vessel density can be downgraded in tumor microenviroment by herbal extract preparation from Ginseng, Herba Agrimonia, Hairyvein and Arginine etc...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152677/economic-burden-of-common-adverse-events-aes-associated-with-metastatic-colorectal-cancer-mcrc-treatment-in-the-united-states-us
#2
Jane Chang, Annie Guerin, Sherry Shi, Ed Wang, Justin Yu, Christopher Ngai
: 21 Background: Treatments for mCRC have distinct safety and tolerability profiles. Common AEs associated with mCRC treatments may compromise the course of treatment, worsen quality of life, and increase healthcare resource utilization and costs. This study assessed the costs of common AEs in mCRC patients (pts) in the US. METHODS: Adult mCRC pts treated with chemotherapy (chemo) or targeted therapies were identified from the Truven MarketScan databases (2009 - 2014)...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28149756/anti-angiogenetic-therapies-for-central-nervous-system-metastases-from-non-small-cell-lung-cancer
#3
REVIEW
Consuelo Buttigliero, Valentina Bertaglia, Silvia Novello
Central nervous system (CNS) metastases are common in patients with advanced non-small cell lung cancer (NSCLC), occurring in 24% to 44% of patients in the course of their disease and confer significant morbidity and mortality. Systemic therapies have been deemed ineffective in brain metastases (BM) under the hypothesis that the blood-brain barrier (BBB) limits their delivery to the brain. Angiogenesis, which is mainly mediated by vascular endothelial growth factor (VEGF) pathway, is crucial for tumor survival, growth and invasion both in primary and metastatic brain lesions...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28132880/pseudolaric-acid-b-inhibits-gastric-cancer-cell-metastasis-in-vitro-and-in-haematogenous-dissemination-model-through-pi3k-akt-erk1-2-and-mitochondria-mediated-apoptosis-pathways
#4
Dan Wang, Yan Xin, Yanqiu Tian, Wenhui Li, Dan Sun, Yi Yang
Pseudolaric acid B (PAB) is the major bioactive constituent in the root bark of Pseudolarix kaempferi and has been reported to have cytotoxicity against tumor cells. Our in vivo experiments showed that PAB could inhibit gastric cancer cell lung metastasis in a nude mouse haematogenous dissemination model. To evaluate the anti-metastasis mechanism of PAB in gastric cancer cells, cytological experiments were performed. The results showed that PAB could inhibit the adhesion ability to matrigel, migration, invasion and colony formation ability of BGC-823 and MKN-45 cells...
January 26, 2017: Experimental Cell Research
https://www.readbyqxmd.com/read/28131635/effect-of-combined-therapy-inhibiting-egfr-and-vegfr-pathways-in-non-small-cell-lung-cancer-on-progression-free-and-overall-survival
#5
Tao Jiang, Meng Qiao, Fei Zhou, Shengxiang Ren, Chunxia Su, Caicun Zhou
BACKGROUND: To investigate the effect of combined epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) receptor (VEGFR) pathway inhibitors on progression-free survival (PFS) and overall survival (OS) in patients with non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS: We included 15 randomized clinical trials that had compared the combination of EGFR tyrosine kinase inhibitors and anti-VEGF/VEGFR therapy with different control groups...
December 29, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28117425/the-role-of-vascular-endothelial-growth-factor-in-small-airway-remodelling-in-a-rat-model-of-chronic-obstructive-pulmonary-disease
#6
Lu Wang, Zhibo Xu, Bin Chen, Wei He, Jingxian Hu, Liting Zhang, Xianzhong Liu, Fang Chen
Small-airway remodelling is one of the most remarkable pathological features of chronic obstructive pulmonary disease (COPD), in which angiogenesis plays a critical role that contributes to disease progression. The endothelial cell-specific mitogen vascular endothelial growth factor (VEGF), as well as its receptors, VEGFR1, VEGFR2, are thought to be the major mediators of pathological angiogenesis, and sunitinib exhibits anti-angiogenesis property through VEGF blockage and has been widely used to treat various cancers...
January 24, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28096694/luteolin-inhibits-lung-metastasis-cell-migration-and-viability-of-triple-negative-breast-cancer-cells
#7
Matthew T Cook, Yayun Liang, Cynthia Besch-Williford, Salman M Hyder
Most breast cancer-related deaths from triple-negative breast cancer (TNBC) occur following metastasis of cancer cells and development of tumors at secondary sites. Because TNBCs lack the three receptors targeted by current chemotherapeutic regimens, they are typically treated with extremely aggressive and highly toxic non-targeted treatment strategies. Women with TNBC frequently develop metastatic lesions originating from drug-resistant residual cells and have poor prognosis. For this reason, novel therapeutic strategies that are safer and more effective are sought...
2017: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28087861/jolkinolide-a-and-jolkinolide-b-inhibit-proliferation-of-a549-cells-and-activity-of-human-umbilical-vein-endothelial-cells
#8
Lei Shen, Shan-Qiang Zhang, Lei Liu, Yu Sun, Yu-Xuan Wu, Li-Ping Xie, Ji-Cheng Liu
BACKGROUND Jolkinolide A (JA) and Jolkinolide B (JB) are diterpenoids extracted from the roots of Euphorbia fischeriana Steud and have been shown to have anti-tumor activity. However, their effects on the ability of tumor cells to invade blood vessels and metastasize remain largely unknown. Investigations into the effects of JA and JB on the angiogenesis of tumor tissues may facilitate the identification of new natural drugs with anti-tumor growth and metastasis activities. MATERIAL AND METHODS We used different concentrations of JA and JB (20 μg/ml, 40 μg/ml, 60 μg/ml, 80 μg/ml, and 100 μg/ml) to stimulate A549 cells and then studied the effects on the growth and metastasis of lung cancers...
January 14, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28063005/albendazole-inhibits-hif-1%C3%AE-dependent-glycolysis-and-vegf-expression-in-non-small-cell-lung-cancer-cells
#9
Fang Zhou, Jin Du, Jianjun Wang
Albendazole (ABZ) has an anti-tumor ability and inhibits HIF-1α activity. HIF-1α is associated with glycolysis and vascular endothelial cell growth factor (VEGF) expression, which plays an important role in cancer progression. These clues indicate that ABZ exerts an anti-cancer effect by regulating glycolysis and VEGF expression. The aim of this study is to clarify the effects of ABZ on non-small cell lung cancer (NSCLC) cells and explore the underlying molecular mechanisms. The expression levels of HIF-1α and VEGF were detected using western blot analysis, and the effect of ABZ on glycolysis was evaluated by measuring the relative activities of hexokinase (HK), pyruvate kinase (PK), and lactate dehydrogenase (LDH) and detecting the production of lactate in A549 and H1299 cells...
January 7, 2017: Molecular and Cellular Biochemistry
https://www.readbyqxmd.com/read/28055269/targeting-the-pd-1-pathway-a-new-hope-for-gastrointestinal-cancers
#10
Burak Bilgin, Mehmet A N Sendur, Muhammed Bülent Akıncı, Didem Şener Dede, Bülent Yalçın
BACKGROUND: VEGF, HER2 and EGFR targeted agents are currently used in gastric, esophageal and colorectal cancers. However, treatment outcomes are still poor in most gastrointestinal (GI) cancers. Immune checkpoints are one of the most promising immunotherapy approaches. In this review article, we aim to discuss the efficacy and safety of anti-PD-1/PD-L1 therapies in GI cancers, including gastric, esophageal and colorectal cancer in published or reported recent studies. SCOPE: A literature search was made from PubMed and ASCO Annual Meeting abstracts by using the following search keywords: "nivolumab", "pembrolizumab", "avelumab", "GI cancers" "anti-PD1 therapy" and "anti-PD-L1 therapy"...
January 31, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28000859/131i-labeled-monoclonal-antibody-targeting-neuropilin-receptor-type-2-for-tumor-spect-imaging
#11
Lichun Chen, Liangliang Wang, Jianghua Yan, Chao Ma, Jing Lu, Guoqiang Chen, Shengyou Chen, Fu Su, Weixing Wang, Xinhui Su
As a co-receptor for vascular endothelial growth factor‑3 (VEGF‑3), neuropilin receptor type‑2 (NRP‑2) plays a central role in lymphangiogenesis and angiogenesis. Recently, mounting data of evidence show that NRP‑2 is overexpressed in several human cancers, and its overexpression is often associated with poor prognosis. Therefore, it is necessary for us to develop an affinity reagent for noninvasive imaging of NRP‑2 expression because it may be possible to provide early cancer diagnosis, more accurate prognosis, and better treatment planning...
February 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/27999195/molecular-and-functional-evaluation-of-a-novel-hif-inhibitor-benzopyranyl-1-2-3-triazole-compound
#12
Kyunghye Park, Hye Eun Lee, Sun Hee Lee, Doohyun Lee, Taeho Lee, You Mie Lee
Hypoxia occurs in a variety of pathological events, including the formation of solid tumors. Hypoxia-inducible factor (HIF)-1α is stabilized under hypoxic conditions and is a key molecule in tumor growth and angiogenesis. Seeking to develop novel cancer therapeutics, we investigated small molecules from our in-house chemical libraries to target HIF-1α. We employed a dual-luciferase assay that uses a luciferase (Luc) reporter vector harboring five copies of hypoxia-responsive element (HRE) in the promoter...
January 31, 2017: Oncotarget
https://www.readbyqxmd.com/read/27988457/in-vitro-and-in-vivo-activity-of-lucitanib-in-fgfr1-2-amplified-or-mutated-cancer-models
#13
Federica Guffanti, Rosaria Chilà, Ezia Bello, Massimo Zucchetti, Monique Zangarini, Laura Ceriani, Mariella Ferrari, Monica Lupi, Anne Jacquet-Bescond, Mike F Burbridge, Marie-Jeanne Pierrat, Giovanna Damia
The fibroblast growth factor receptor (FGFR) pathway has been implicated both as an escape mechanism from anti-angiogenic therapy and as a driver oncogene in different tumor types. Lucitanib is a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptors 1 to 3 (VEGFR1 to 3), platelet derived growth factor α/β (PDGFRα/β) and FGFR1-3 tyrosine kinases and has demonstrated activity in a phase I/II clinical study, with objective RECIST responses in breast cancer patients with FGFR1 or FGF3/4/19 gene amplification, as well as in patients anticipated to benefit from anti-angiogenic agents...
December 15, 2016: Neoplasia: An International Journal for Oncology Research
https://www.readbyqxmd.com/read/27974353/vegf-blockade-enhances-the-antitumor-effect-of-brafv600e-inhibition
#14
Valentina Comunanza, Davide Corà, Francesca Orso, Francesca Maria Consonni, Emanuele Middonti, Federica Di Nicolantonio, Anton Buzdin, Antonio Sica, Enzo Medico, Dario Sangiolo, Daniela Taverna, Federico Bussolino
The development of resistance remains a major obstacle to long-term disease control in cancer patients treated with targeted therapies. In BRAF-mutant mouse models, we demonstrate that although targeted inhibition of either BRAF or VEGF initially suppresses the growth of BRAF-mutant tumors, combined inhibition of both pathways results in apoptosis, long-lasting tumor responses, reduction in lung colonization, and delayed onset of acquired resistance to the BRAF inhibitor PLX4720. As well as inducing tumor vascular normalization and ameliorating hypoxia, this approach induces remodeling of the extracellular matrix, infiltration of macrophages with an M1-like phenotype, and reduction in cancer-associated fibroblasts...
February 2017: EMBO Molecular Medicine
https://www.readbyqxmd.com/read/27959445/delphinidin-inhibits-angiogenesis-through-the-suppression-of-hif-1%C3%AE-and-vegf-expression-in-a549-lung-cancer-cells
#15
Mun-Hyeon Kim, Yun-Jeong Jeong, Hyun-Ji Cho, Hyang-Sook Hoe, Kwan-Kyu Park, Yoon-Yub Park, Yung Hyun Choi, Cheorl-Ho Kim, Hyeun-Wook Chang, Young-Ja Park, Il-Kyung Chung, Young-Chae Chang
Delphinidin, a polyphenol that belongs to the group of anthocyanidins and is abundant in many pigmented fruits and vegetables, possesses important antioxidant, anti‑inflammatory, anti-mutagenic and anticancer properties. In the present study, we investigated the inhibitory effects of delphinidin on vascular endothelial growth factor (VEGF) expression, an important factor involved in angiogenesis and tumor progression, in A549 human lung cancer cells. Delphinidin inhibited CoCl2- and epidermal growth factor (EGF)-induced VEGF mRNA expression and VEGF protein production...
February 2017: Oncology Reports
https://www.readbyqxmd.com/read/27940520/exploring-the-benefit-risk-associated-with-antiangiogenic-agents-for-the-treatment-of-non-small-cell-lung-cancer-patients
#16
REVIEW
Razelle Kurzrock, David J Stewart
Following the approval of bevacizumab, an antibody targeting VEGF-A, for advanced non-squamous non-small cell lung cancer (NSCLC) in 2006, intensive efforts were put into the clinical development of antiangiogenic agents for NSCLC. Currently, the other antiangiogenic agents approved for NSCLC are ramucirumab, a VEGF receptor-2 (VEGFR-2)-targeting antibody indicated for both squamous and non-squamous NSCLC in the United States, and nintedanib, an anti-VEGFR-1/2/3, platelet-derived growth factor receptor-α/β, fibroblast growth factor receptor-1/2/3 angiokinase inhibitor indicated for adenocarcinoma of the lung in the European Union...
December 9, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27930983/sargassum-fusiforme-polysaccharides-inhibit-vegf-a-related-angiogenesis-and-proliferation-of-lung-cancer-in-vitro-and-in-vivo
#17
Huiling Chen, Ling Zhang, Xiange Long, Peifei Li, Shengcan Chen, Wei Kuang, Junming Guo
Sargassum fusiforme (Harv.) is a brown alga belonging to the Sargasaceae family. The Sargassum fusiforme polysaccharides (SFPS) have demonstrated good anti-tumor and immunomodulatory activity. However, the underlying mechanisms of its anti-tumorigenesis, especially the anti-angiogenic activity is yet to be established. In the present study, we attempted to determine the effects of SFPS on the human lung adenocarcinoma SPC-A-1 cells and its xenograft model. The results showed that SFPS provides a concentration-dependent inhibition of SPC-A-1 cell proliferation in in vitro and the tumor growth in in vivo studies...
January 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/27890369/anti-tumor-activity-of-tanshinone-iia-in-combined-with-cyclophosphamide-against-lewis-mice-with-lung-cancer
#18
Qi Li, Ke Hu, Si Tang, Li-Fang Xu, Yu-Chuan Luo
OBJECTIVE: To explore the anti-tumor activity of tanshinone IIA in combined with cyclophosphamide against Lewis mice with lung cancer and the effect on cellular immune function. METHODS: Lewis tumor cells were inoculated subcutaneously into the right armpit of mice in each group (n = 20) to establish Lewis lung cancer mice model. After model establishment, mice in the model group were given normal saline by lavage, qd. Mice in treatment I group were given intraperitoneal injection of Tan IIA, 15 mg/kg, qd...
November 2016: Asian Pacific Journal of Tropical Medicine
https://www.readbyqxmd.com/read/27876017/increased-wnt5a-in-squamous-cell-lung-carcinoma-inhibits-endothelial-cell-motility
#19
J Rapp, E Kiss, M Meggyes, E Szabo-Meleg, D Feller, G Smuk, T Laszlo, V Sarosi, T F Molnar, K Kvell, J E Pongracz
BACKGROUND: Angiogenesis is important both in normal tissue function and disease and represents a key target in lung cancer (LC) therapy. Unfortunately, the two main subtypes of non-small-cell lung cancers (NSCLC) namely, adenocarcinoma (AC) and squamous cell carcinoma (SCC) respond differently to anti-angiogenic e.g. anti-vascular endothelial growth factor (VEGF)-A treatment with life-threatening side effects, often pulmonary hemorrhage in SCC. The mechanisms behind such adverse reactions are still largely unknown, although peroxisome proliferator activator receptor (PPAR) gamma as well as Wnt-s have been named as molecular regulators of the process...
November 23, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27863726/-met-receptor-inhibition-hope-against-resistance-to-targeted-therapies
#20
REVIEW
Audrey Hochart, Pierre Leblond, Xuefen Le Bourhis, Samuel Meignan, David Tulasne
Overcoming the drug resistance remains a crucial issue in cancer treatment. For refractory patients, the use of MET receptor tyrosine kinase inhibitors seems to be hopeful. Indeed, important mechanisms underlying drug resistance argue for association of MET inhibitors with targeted therapies, both on first-line to prevent a primary resistance and on the second line to overcoming acquired resistance. Indeed, met gene amplification is the second most common alteration involved in acquired resistance to anti-epidermal growth factor receptor (EGFR) therapies in non-small cells lung cancer (NSCLC)...
February 2017: Bulletin du Cancer
keyword
keyword
17920
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"